streetsmart
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi Warrenbucket,
Just so you know i lodged a complaint against SLBrown and IHUB for allowing SLbrown to moderate NPHC board in such a fashion as to manipulate the image of NPHC as a high value and high growth oppourtunity. I think you should consider legal action to recoup some of your losses. I have a long documented account of the goings on on this board and will happily facilitate you shoudl you wish to try recover some of those losses.
This is one of several complaints I posted way back in 2010.
DAN,
I have a serious issue with the moderator in NPHC.
He has caused one investor lose serious money. The stock was at .22 cents and since this post from SlBrown the NPHC moderator the stock has fallen to .145 cents and teters arounsd .16.
,
Please also see 6035, 6036, 6037, from SLBROWN where he claims the share price is valued at .87 cents when independent analysts have projected with high growth at most it is worth .04 cents. SLBROWN goes on to tell people not to sell. His guidlines is biased in the extreme and the post below shows that SLBROWN has a serious agenda to hype and pump NPHC. He is not an appropaite moderator for NPHC specifically.
Note: warrenbuckets posts are all very normal.
Here is the post:
Posted by: slbrown Date: Tuesday, June 29, 2010 7:46:39 AM
In reply to: warrenbucket who wrote msg# 5778 Post # of 6097
Now that is what I call pure panic warren! Venting your frustrations due to the recent market conditions that have caused NPHC to slip much lower than many have predicted isn't helping to turn this situation around at all. It only helps to instill more fear and drive the pps lower and panic statements just scare away investors who may wander over to this board for some DD and when they see statements such as these, they will surely not buy if they do not understand the situation fully. So, in fact you are helping to fuel the panic selling as some others are doing and contributing to the declining pps, which imo is due to a temporary market condition, which will hopefully turn around soon and time will tell soon enough. If you compare NPHC's chart to the Nasdaq you will see a direct correlation to the two, because NPHC investors are more of the savy type who tend to follow the market closely and despite knowing that NPHC is a great investment, they will pull their money out while waiting for the market to rebound and buy in lower. The fact remains that this is a very good investment for the long haul and you will only lose if you sell at these levels due to market fear alone. This will take some time, but know this; NPHC has continued to push forward and expand with increasing sales and distribution. Even I bought a substantial chunk of shares around the .48 area, as I did not expect this to happen, but I am smart enough not to panic, but rather to continue to average down when the opportunity arises. That my friend is the nature of playing the stock market and keeping your head at a time like this is critical, if you are to be successful in the long haul. JMHO! Cheers!
PS: Stan_12 has a grasp on the situation and I think he is spot on and you might want to concentrate more on his take, instead of those who try instilling fear and panic
Cobraman! When is the third quarter report coming out.
When is the third Quarter coming out ?
Rik was certainly overly optimistic but the question remains is cobroxin as ood as he says it is. Considering we wont hang on his every word then clinical trials must be conducted.
They could use the money to fund clinical trials. Instead of hiding behind a loop hole in the FDA regulations, they should get the clinical trials underway. We have yet to see the next 2 quarter's which will really tell us what's happening.
Cobraman.. I can understand your fustration with this company and even this forum as there are some real stubborn points of view shoved in peoples face by a hard core group of die hards.
However there is more than a glimmer of hope for this company. They have recently won a grant which i expect they will invest in clinical trials. From your point of view they have either have hustled the QTDPP or the QTDPP is throwing around tax payers hard earned cash faster than they can get it. I would call this hope or a Goverment subsidy gone desperatly wrong. Whilst i agree they are not the best at Marketing they must be doing something right.
Nutra Pharma Awarded Grant Under the Qualifying their pain products. There is also the possibility they will Therapeutic Discovery Project Program.
How is every one doing! The third quarter is out after DEC 18th 2010; is that correct? What do people expect it is going to be and why!
I am hoping that we see a turn around going into the fourth quarter. However if the third dissappoints then what will be the catalyst for a fourth quarter run up.
AIB might have been a more technical.I am not sure. Today might be very interesting for the banks.
http://www.rte.ie/news/business/morningrep/download/1115goodbody.pdf
BOI published an IMS on Friday morning. We commented on the details then, but to recap, the
move in the LDR from 145% to 160% was the key point for us in the statement. This implies that
BOI saw about €10bn of deposit outflows since H1 (deposits were €84bn), mainly through its
capital market business in August and September, though they appear have stabilised since
then. BOI indicated that its un-pledged eligible collateral at the half year was €25bn. Q3 deposit
outflows sees this figure now reside at only about half this figure, limiting wiggle room (has
c.€20bn net monetary authority drawings).
BOI’s conference call hinted at lower margins in 2011, emphasising the difficulties still on
domestic deposits. Our earlier expectation was for normalised margins in 2014, about 12 months
later than BOI’s guidance. However, the prospect of weaker economic activity due to our recent
GDP downgrades (slower new business levels and lower redemptions of cheap product) and
higher funding costs was already starting to put pressure on our own estimates, so we are now
pushing out the year of mid-cycle margins a further 12 months to 2015, though in the short term,
funding cheaply from monetary authorities eases some P&L strain. On credit, BOI was fairly
comforting on the current impairments trends, but we continue to fret about our recent GDP
downgrades and the upcoming 4 year austerity plan and the prospect of an elongated credit
cycle.
Substantially higher Irish bond yields and a weakening economy raising fears on future
impairments (and income) is compounded by the market’s lack of comfort with a 7% core equity
trough for the Irish banks. So capital is firmly back on the radar, compounded by the domestic
Central Bank Governor’s comments earlier this week about the attractiveness of
“overcapitalisation”. Firstly, taking the capital ratio in its own right, expectations for the European
sector are now closer to a 9% core equity range (on a Basel III basis). Simplistically targeting
9% implies that our previous fair value of €0.75 (on 7% target) drops by 15c to €0.60. Secondly,
stressing the balance sheet for the weaker macroeconomic prospects and higher funding costs,
for instance, modelling the Central Bank’s stressed mortgage loan loss level (5%, though we
note the comments in the media this morning that the Cardinal consortium looking at the EBS
has stressed the mortgage book to 7% mortgage losses) and a one-third increase in everything
else, combined with weaker income, would reduce the fair value by a further 45%. While the
reality may well reside somewhere in the middle, the market is looking for a “circuit breaker” in
terms of sentiment for the Irish banks. Therefore, taking a cautious view on capital may be used
to address these concerns. Bear in mind that the stressed losses may fail to materialise, but the
CB looks to be setting up a preference for too much capital rather than too little in any case. The
share price resides somewhere in the middle of these two ranges and, with valuations fraught
with huge variability and capital still on the radar, its hard to be getting any more excited than an
http://www.rte.ie/news/business/morningrep/download/1115davy.pdf
Bail-out chatter persists; guaranteed banks' reliance on ECB increases to c.€80-85bn
Stephen Lyons
Bail-out chatter, which reached fever-pitch on Friday with Reuters reporting that Ireland was in discussions to tap the European
stability fund, persisted over the weekend. This was despite the official response from the Minister for Finance on Friday,
reiterated again by the Department of Finance last night, that no such external support had been sought. Despite the fact that
Ireland is fully-funded until the middle of next year, bail-out concerns are likely to dominate again this week with euro zone
finance ministers set to meet and as markets watch for contagion amongst the peripheral countries. The Spanish auction on
Thursday will be closely watched after Portugal was forced to pay its highest ever yield at an auction last week. And Eurostat is
widely expected to revise upwards Greece's 2009 budget deficit from the current estimate of 13.6% of GDP. The Financial
Times also reports this morning that senior European officials held discussions late into yesterday evening to decide whether
Ireland needed an aid package before the market opened, although talks broke up without any action being taken.
Concerns over the domestic banks' reliance on ECB borrowings further added to sovereign concerns, with the Irish Central
Bank reporting that lending to credit institutions in Ireland — which includes IFSC banks — increased to €130bn at the end of
October, from €118bn at the end of September. This figure was particularly relevant given the €10bn outflow of deposits
experienced by BKIR since end-June. Much of the outflow appears to be overseas as Central Bank figures showed that
domestic deposits fell by €5bn between June and end-September — the period of stress for BKIR. We will not have the figure
for the domestic market credit institutions' borrowings from the ECB for October until the end of this month. However, if we
assume that the €12bn increase was all in this component, it would put this figure at €95bn and we estimate the number for
the six guaranteed Irish banks to be between €80bn and €85bn (excluding RBS, Lloyds, KBC and Danske).
DUBLIN (Reuters) - Bank of Ireland looks set to emerge as the dominant force in Irish banking, with any overseas investment in rivals unlikely to materialize until fears are allayed over the country's economic recovery.
With Allied Irish Bank, once Ireland's biggest company, now facing majority state-control and foreign lenders baling out of the Irish market, Bank of Ireland has an unprecedented opportunity to seize control, analysts say.
"It is the natural winner. There's a fundamental opportunity there," said Collins Stewart analyst Gary McCarthy. "It has the strongest capital position and can capitalize on the problems that the (domestic) competition have as well as international competition having left their banking franchises behind."
In a research note last month Goldman Sachs put an implied valuation of 7.4 billion euros ($9.7 billion) on the stock based on forecast 2013 earnings. That is almost three and half times its current market value of 2.2 billion euros.
"On our estimates BOI is well placed to take advantage of eventual macro recovery and its current valuation of 3.6 times recovery earnings (2013) offers meaningful upside," it said.
Goldman Sachs has a 'buy' recommendation on Bank of Ireland but a 'neutral' recommendation on Allied Irish Banks where it sees limited upside for the bank's near-term share price performance given that the state is expected to take a stake of over 90 percent by underwriting a 5.4 billion-euro rights issue.
Goldman Sachs said Allied Irish Banks trades at between six and nine times its forecast recovery earnings for 2013 while European banks on average trade at nine times 2011 earnings and 6.5 times their 2012 earnings.
I think this is why AIb is dropping. 2011 Q1 this should be prime to run. Please check the IRE ( bank of ireland thread) for links to irish broker reports etc.
AIB has hired Swiss investment bank UBS to help advise on its planned share sale in the
fourth quarter. The bank joins Morgan Stanley, JP Morgan and Goodbody Stockbrokers as
advisers, as AIB expects to raise as much as €3bn in equity from investors and Ireland’s
government. AIB are currently trying to raise €7.4bn, where €2.5bn is expected from the sale
of Bank Zachodni WBK, by year end in order to meet the financial regulator’s target.
Use the following link to access the latest irish brokerage reports on Publicly traded Irish companies such as AIB and Bank of Ireland.
The second link is the latest business news from RTE ireland.
http://www.rte.ie/business/brokerreports.html
http://www.rte.ie/business/index.html
Sounds Great...I wonder where the next bubble is going to be. I suspect technology Sector and likely Green technology.
Read my previous post CNGREEN and please read the very end Part of that reply and don't bother me about this anymore.
Well, Someone brought the bacon home. Well done Cobraman.
Sounds like you have carved out a decent career for yourself. I would say the recession has created some difficult times.
cngreen? ( your Post)
There should be follow up in sales of Cobroxin regardless of adevertising. People that have tried and found it worked should be re-purchasing. They sold a fair number of products in the last few quarters. Why has this quarter being such a slump for existing customer's.
Perhaps but AOB has a relatively high Beta. So it reacts with more volatility. When the market does bounce back AOB could deliver a nice 30%.
Highest Upside Potential in the Personal Products Industry Detected in Shares of Aob etc..
Below are the top five companies in the Personal Products industry as measured by the potential gains between the current stock price and the projected average analyst target.
Revlon (NYSE:REV) has a potential upside of 74% based on a current price of $10.92 and an average consensus analyst price target of $19.
American Oriental Bioengineering (NYSE:AOB) has a potential upside of 66.7% based on a current price of $2.25 and an average consensus analyst price target of $3.75.
Medifast (NYSE:MED) has a potential upside of 57.2% based on a current price of $26.72 and an average consensus analyst price target of $42.
China-Biotics (NASDAQ:CHBT) has a potential upside of 53.3% based on a current price of $14.36 and an average consensus analyst price target of $22.
Physicians Formula Holdings (NASDAQ:FACE) has a potential upside of 52.8% based on a current price of $3.12 and an average consensus analyst price target of $4.77.
SmarTrend is bearish on shares of AOB and our subscribers were alerted to Sell on January 27, 2010 at $4.05. The stock has fallen 44.4% since the alert was issued.
State Street Said in Talks to Buy Bank of Ireland's Asset-Management Unit
State Street Corp., the third- largest custody bank, is in talks to acquire Bank of Ireland’s asset management business, according to three people familiar with the matter.
Macquarie Group Ltd, which had been in negotiations to take over the Dublin-based unit, dropped out, according to two of the people, who declined to be identified because the negotiations are private. No agreement has been reached and the sale may take months, said two of the people.
The European Commission ordered the sale of the unit as a condition of approving a government bailout of Bank of Ireland. The unit, also known as BIAM, controlled 25 billion euros ($31.8 billion) of assets as of April 16, down from 57.5 billion euros in 2004, when it was Ireland’s largest investment manager.
Scott Powers, chief executive officer of State Street Global Advisers, said in an interview published on Aug. 3 that the index funds specialist is looking for acquisitions to expand actively managed investments and cut reliance on passive funds. BIAM is primarily an active manager, while State Street is the second-biggest U.S. provider of index funds after BlackRock Inc.
State Street spokeswoman Carolyn Cichon declined to comment, as did Bank of Ireland spokesman Dan Loughrey and Karen Smith, a London-based spokeswoman for Macquarie.
My mother had migrain most of her life. Severe Migrain so it was not easy to live with and I am sure we suffered. If this could have made a difference it would have been great.
Yet we really don't know how effective this is a pain reliver specifically. I cannot guarantee a migrain sufferer that cobroxin will cure his/her migrain.
We simply don't know. That makes it a problem for me. Tiger balm and bio freeze are both highly specific pain relivers. They are not claiming to prevent a host of problems and that is why i wonder if Cobroxin (while working for specific pain i.e artrithis) is otherwise a once off test purchase for many people.
I wouldn't invest in a company that s only product was tiger balm.
You would know alot more about that than I would, SL. My concern would be cobroxin is a very new product and the first product Nutra Pharma have ever produced. They are entering the pain market, where people require medication that is proven effective. People don't like to be test subjects when they are in pain.
and st66
NUTR and other brands names are well established and focus on niche markets. As you said they have conducted trails on some of their products. They might have strated off without clincially proven products and worked hard to get recognition or they might have started with clinically proven products. Now they simply have enhanced their range with newer products that wouldn't require testing based on the niche they are already proven to be successful in.
I wouldn't say they advertise this and rely on their established brand image to push additional produce. It is an good example and i am not challenging you to give other examples and i think NUTR is a fine example.
Those other OTC products that don't have placebo trials are not going to make an investor rich. Cobroxin is expected to outperform sales revenue of these other products.
Higher expectations require higher standards.
No! You fail to forsee the problems before they arise. You also fail to see them as they unfold. Then after they happen you fail to learn from them. Your still replying to my posts in a manner that implies your analysis of this company supersedes anyones analysis no matter how pertinent.
I understand you have been in the business and I would say your... brains have more stuff in them from the business.
Knowing the business hasn't helped you forsee Nutra Pharma's problems although I think at another level you knew alot more about what could go wrong but were too biased to share or divulge your thoughts on that with everyone else.
Which is unfair as this is the stock market and doesn't just concern the pharmaceutical business. As noted earlier this is a high beta stock with a high O/S and 34 and 10 million warrants sitting at .08 and ten cents respectively.
Any disruptions to the plans or even strong market fluctuations during a period where there is no news or uncertainty causes huge volatility.
Your behaviour and some others is to act as if any post that suggests a disruption or problem is wrong because that poster is delibertly sending out a message that there is a disruption or problem and trying to lower the share price.
Do you not see how hypocritical that is. If you think it is so volatile that a comment in post on a internet forum can send it bouncing all the over the place then you have to see that your tolerances are too coiled too tight and constant cheerleading has wasted one of your skills from contributing.
Whats your position with this company may I ask. Are you involved as more than just a speculator.
I have Shares LONG but I did ride this rollercoaster just to break even after I realised it would not suit my time frame waiting to recoup my loss. I am neither short nor long and had to take considerable risks to rebalance my account.
I also felt your posts were misleading and far too optimistic and i think you deserve to share some blame for people losses. As you are the one who places so much emphasis on the effect what people post will have on the share price.
Basically:
A high beta stock is more sensitive to market fluctuations.A stock with a beta of 1 will have more or less the volatility that is in line with say the S&P 500 index or other relevant index. A stock with a beta of 1.5 is theoretically 50% more volatile than the index.?
NPHC has I think a beta of 4.5.
There are posters here that know the business alot better than I do:
Now I have to wonder why XCHO would ever agree to advertise Corboxin. Also why Nutra Pharma would entrust the marketing of their product on the promise of high growth and revenues.
That was surely a risky gamble.
If Nutra Pharma have never conducted Placebo trials; then nutra pharma and nutrapharma alone have the neccessary clinical undertanding of this product and nutrapharma would be the sole proprietar
As the manufacturer and the owner of the patent, formula, brand name, and trademark associated with the product it is Nutra Pharma's proprietary medicine.
Any third pary would expect clinical trials ( placebo trials) to counteract the bias Nura Pharma would have for wanting their product ( propietary medicine ) advertised and distributed by a third party
I can no logical reason why XCHO should risk their money on a propietary medicine they do not have any rights to and do not have the mecial expertise to test themselves.
Basically it comes down to whether you can confidently say that Frank Rizzo and XCHO believe wholeheartily in this product. They have no scientific trials to satisfy their concerns. Nutra Pharma were at the very least naive and the worst arrogant to think anyone has to dedicate their time money and reputation on their product.
XCHO achieved sales of 1 million for NPHC and none of this money was re-invested into clinical trials. XCHO have achieved their primary goal but the missing cog in the marketing process must be without a doubt..concrete clicial trials.. and without which no one should be expected to undertake the burden that the absence of these trials leaves.
Nutra pharma will never find a distributor that will take on this risk. I am not sure what contract they have with XCHO but don't just assume XCHO are at fault. It would appear to me NPHC have made an error and one which they wont recover from.
I am concerned about now again hearing about NPHC's two consultants ( in the 10 Q) that are critical to the business that are costing most of the fees. I would fire them and save the millions they are costing and undertake immediately to establish their product at the standard already established by competeing drug products otherwise cobroxin is going to vanish from the shelves.
That's at the very least reassuring to hear Zeolite works. I like that someone bites your hand off for making that effort. Thanks for your post. Rik Dietsche is involved with Zeolite but I am not sure NPHC own it.
I agree it might be long term and folks since it's such a long long term investment it raises my suspicion that you cannot argue for a Placebo trial,retail chains,Warrants,outstanding shares,advertising on this forum without a tantrum being thrown...
The company comes across as inadequate because they won't do a Placebo trial. I think it could be done cheaply and within one quarter.. we are talking about Pain over 3 months would be sufficent to get an idea.
I would say many investors won't hang about waiting for Nutra Pharma to do this. Rik comes across as somone who markets a product and then sells as many as cheaply as he can and then moves on to another project.
I.e His last project where he marketed zeolite, Is cobroxin and Nyloxin just another marketing ploy?
I know that's sounds unfeasible considering they have a pipeline but that's an impression I get.
Then the inability to do any testing actually makes me wonder if that is all cobroxin is. An old recipe cooked to flog on the market for a quick buck.
The reason I have these questions is the way soemtimes alot of posters appear out of thin air to defend NPHC from some alleged attack and then vanish again. We are constantly assured by posters that everything is scientifically proven and legit and this company will make a fortune and the stock will fly to the moon.
Never ever have any of these people backed up anything with LINKS or evidence to prove anything they say. Where has it been scientifically proven or clinically proven. The cobroxin website just proves it hasn't ever been tested as Cobroxin. The latest clinical test was on a cancer study of cobra venom in Asia in 2008 when cobroxin did not even exist. It's a fraud to use asian studies as an example that cobroxin has been clinically tested.
They have no placebo Trial. XCHO might have saved alot of money from not advertising this product. I have yet to see if there is a revision to the last quarter's sales, but I hold little hope of any revision realistically making any difference after 3 month's.
The bottom line is this:
Cobroxin was selling, Cobroxin even ran up the best sellers on Amazon and people tried it and for whatever reason they are not continuing to purchase it. It has since fallen on Amazon best sellers list. IMO: 6 out of 8 people that tried cobroxin have not since bought it again.
Sales revenue of 150,000 compared to 500,000 - 800,000 shows no repeat sales despite allegedly also being available in Walgreens and CVS, and I gather from the Nutra pharma PR many of those stores did not stock it as I suspected.
That is an alarming failure and in most part because XCHO have no placebo trials to work with and demonstrate with. Don't try kid yourself that a cheap advertising campaign will make this a blockbuster. Marketing is important but not as important as the proven quality of a product.
If sales continue to fall then Cobroxin won't even have customers to post their reviews. The only ridiculous comment I or anyone ever made on this forum is that this will quadruple revenue.
Clearly even a growing revenue is not going to happen which is extremely worrying consdering that even the most optimistic analysts cited growth as one of the very few factors NPHC had going for it.
Dumping XCHO is just a convient exit. Nutra Pharma could have compiled and conducted a Placebo trial in the time since the last person here posted their concerns. NPHC have only themselves to blame.
It has run up 5% today...
I followed this product on Amazon just to get a rough idea of how well it was selling. It peaked some time ago and noticably began to fall back down the bestsellers list in last 7 week's.
While not a great indication it is at least updated evey few days or weekly by Amazon.
If the advertising has a positive effect we might see this slow its decline in the bestsellers list and start to show improvments.
Do you mean this as a moderator or do you mean this as poster who would like to see NPHC $5 - $10. How has the forum gone to the dogs?
You promised these people not only a profit but amazing revenue. Why don't you Man up and admit it.
Well Micron technology has worked out very good today. I got in on friday. A very risky trade but worked out great. This might be a reversal or a just a bearish correction... have to wait and see.
Why Micron Technology Stands Out
Article is from JUNE but is just as relevant now that we have higher upside:
Semiconductor stocks have rebounded strongly over the past week. This is evident in the performance of the Philadelphia Semiconductor Index, which as of Wednesday’s close is up 12.4% since closing at its lowest level of the year on June 9th. Given this surge, it’s natural to wonder whether you’ve missed the opportunity to get in.
I don’t think so. True, it would have been a lot easier a few days ago, but there are still bargains to be had if you do your due diligence and don’t mind stomaching some short term volatility. Indeed there are still several constituents within the index that look attractive from a valuation standpoint. However, one stock in particular really stands out.
Micron Technology (MU) is a global maker of semiconductors that store and retrieve data used by the computing, consumer, networking, telecommunications, and imaging markets. In technical terms, it manufactures and sells dynamic random access memory (DRAM) and NAND flash memory products.
Though you may not be aware of it, these products are found in the computing hardware you probably use every day such as PCs, smartphones and videogame consoles. Basically, DRAM is system memory. And usually the more you have, the better. This is because it allows you to run more applications on the system at the same time and process/playback higher quality media without compromising speed. NAND flash are solid state (i.e. no moving parts) data storage products most commonly found in memory cards used in digital cameras and other portable electronic devices. They are also the main memory component in the portable USB “thumb” drives everyone seems to carry around on their key chains these days.
While MU derives a small portion of its revenues from other businesses, the key driver of the company’s future success will be growth in these main memory products. This growth took a major detour during the economic downturn as recession-related cut backs in spending by both businesses and consumers resulted in weak demand for memory products in fiscal 2009.
However, IT infrastructure investment by corporations has begun to rebound. Growth has also benefited from the larger memory requirements associated with newer, more visually and feature rich computing platforms and software applications, and the storing and play back of higher quality media files such as high definition video.
This growth is evident in MU’s recent operating performance. Fiscal 2010 Q2 net sales jumped 97.5% year-over-year and 12.7% sequentially to $1.96 billion. Memory product sales grew 106%. This was led by DRAM sales, which climbed 173%, boosted by 105% rise in gigabits sold and a 38% rise in average selling prices (ASPs). NAND sales were up 32% as a 72% growth in gigabits sold more than offset a 23% decline in ASPs. Operating income was $415 million versus an operating loss of $709 million the prior year, which was negatively impacted by inventory write-downs, restructuring expenses and other special charges. Net income was $365 million or 39 cents per share versus a net loss of $763 million or 99 cents per share in Q2 of fiscal 2009.
As with many tech firms, the key concern is that the current rebound in demand could prove temporary. This would result in lower product demand, as well as, erase the pricing power the industry currently enjoys. Fortunately, pricing should remain strong over the near term due to favorable industry supply/demand dynamics. MU noted strengthening demand from both its computing and networking customers. This strength should continue to fuel investments in IT infrastructure and equipment purchases in the second half. At the same time, distribution channel inventories are at lean levels and industry capacity remains tight.
Over the longer term, file sizes will only continue to grow as preferences for higher quality media files proliferate. Heck, I still remember the 256 megabyte USB drive I was using just a few years ago even as I look at the 4 gigabyte one I have now (which offers 16 times the storage capacity). I can only imagine what storage capacity will be like in another few years.
Additionally, due to their inherent advantages over traditional spinning hard drives, including better performance, lower power consumption, and increased reliability, drives made from solid state flash products should continue to gain in popularity as prices fall and capacities rise. MU noted that initial demand for its C300 RealSSD products have been robust with shipments moving beyond its OEM customer base. Furthermore, the recent acquisition of rival flash memory maker Numonyx increased MU’s scale, expanded its product portfolio, and should result on cost saving synergies when fully integrated.
But perhaps the most attractive thing about MU is simply its valuation. Even with its recent gains, the stock sells at less than 7 times current year expected earnings. That’s cheap in almost any industry and typically unheard of in technology shares. It also compares extremely favorably to one of its closest rivals, Sandisk (SNDK), which sells for double the valuation at 14 times expected earnings despite similar growth prospects for the year.
Disclosure: No position
$15 ha ha :)
This is Great! I am only dissappointed they didn't leave time to get more share .18 - .20. it just rocketed. Nice Gain... I will have to risk averaging up. At least not down anymore.
Great job XCHO.
What quarter are we looking at now for the reaction to advertising. I am aiming for third quarter to be the be the start of the exciting revenue growth we have been looking forward to.
I am excited about this as everyone else and I felt that it was important that Cobroxin was in as many retail chains before advertising commnenced. I was concerned and with Publix on board I am less concerned and XCHO seem to be doing a great job.
With this advertising campaign they should be able to confirm a few more retail chains and perhaps even Wall mart. In fact I would say wall mart is looking very likely.
Great Job XCHO
Stakes could not be higher as Nama is put to the test
( Nama handles all the toxic loans from AIB and BOI (IRE))
A legal challenge to Nama by developer Paddy McKillen could derail the engine designed to pull the banks out of crisis
IT IS 15 months since plans were announced for a State agency to take out the most toxic loans across the domestic banking sector. As of this week, the National Asset Management Agency (Nama) had acquired a quarter of the targeted loans linked to the 33 biggest borrowers.
Nama said this week it had acquired a further [euro]5.2 billion in loans from four of the five participating lenders - Anglo Irish Bank is still working on its second batch of loan transfers - bringing to [euro]20.5 billion the running total on Nama's loan acquisitions - [euro]60.5 billion to go.
But now a legal challenge to the constitutionality of the Nama legislation by one of those 33 borrowers threatens to derail the Government's engine that is pulling the banking system out of its crisis.
Time is also against the State - Nama has to meet February's deadline set by the European Commission to transfer all [euro]81 billion in loans.
The Department of Finance didn't mince its words when it stressed to the Commercial Court on Monday the importance of hearing the judicial review proceedings taken by businessman Paddy McKillen as soon as possible. It pushed the issue to fast-track the case so that Mr Justice Peter Kelly would give it the earliest date possible in the court's busy list.
The stakes are high. McKillen's challenge presents "a very real threat to the vital work of Nama that must continue, and be seen to continue, in order to increase and maintain confidence in the Irish banking sector and thereby strengthen and protect the economy of the State", department official Ann Nolan, a key engineer of Nama, said in a court affidavit.
Both sides must prepare legal arguments and expert witness statements before the case begins on October 5th over an expected four days. A team of legal heavy-hitters has been recruited by McKillen to poke holes in the legislation that the attorney general Paul Gallagher SC had a crucial role in drafting last year.
At issue is whether Nama's procedures trample over the property rights and business interests of good borrowers, and whether they are detrimental to the few businesses whose loans are performing, generating income and being taken over by the State agency.
Economist Peter Bacon designed Nama to buy both good and bad loans by acquiring whole land and development loan portfolios.
The reason for this was the Government had to remove uncertainty about the banks, proving to the financial markets which support them that the institutions had been cleansed of their most toxic assets and so that interest on good loans would pay for servicing the bad.
Some of the financial scaffolding around the Nama structure has collapsed somewhat since the revised draft plan was published earlier this month. It showed that while the price being paid by Nama for the loans had fallen dramatically - the average discount has shot up from 30 per cent to 50 per cent, reflecting the poor quality of the loans - the level of income-generating loans had also dropped, to 25 per cent from 40 per cent last October.
http://www.istockanalyst.com/article/viewiStockNews/articleid/4337824
McKillen's loans - if they are all eventually to transfer - would be among the 25 per cent